文献速递头颈与中枢神经肿瘤

溶瘤病毒治疗胶质瘤的人体临床研究综述

Oncolytic virus in gliomas: a review of human clinical investigations.
PubMed 文献 · Ann Oncol · 2021-03-24

胶质瘤因血脑屏障后免疫豁免微环境及免疫抑制效应而对传统治疗耐药。借鉴肺癌和黑色素瘤免疫治疗的成功,免疫治疗成为胶质瘤潜在治疗方向,其中溶瘤病毒尤其展现前景,PVSRIPO和DNX2401近期获突破性疗法和快速通道认定。本综述汇总了已完成的人体临床研究。

要点

  • 胶质瘤对传统治疗耐药与血脑屏障后免疫豁免及免疫抑制相关。
  • 溶瘤病毒在胶质瘤治疗中展现前景,PVSRIPO和DNX2401获监管特殊认定。
  • 本综述汇总了多种溶瘤病毒已完成的人体临床研究。

核心结论

  • 溶瘤病毒在胶质瘤治疗中展现显著前景,PVSRIPO和DNX2401近期分别获得突破性疗法和快速通道认定。

研究设计与样本

  • 本文为综述,汇总多种溶瘤病毒治疗胶质瘤已完成的人体临床研究。

主要发现

  • 胶质瘤对传统治疗耐药源于血脑屏障后免疫豁免微环境及其对免疫应答的抑制效应。
  • 借鉴肺癌和黑色素瘤等系统性肿瘤免疫治疗的成功,免疫治疗成为胶质瘤潜在治疗方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gliomas remain one of the more frustrating targets for oncologic therapy. Glioma resistance to conventional therapeutics is a product of their immune-privileged milieu behind the blood-brain barrier, in addition to their suppressive effect on the immune response itself. Taking the lead from the growing success of immunotherapy for systemic cancers, such as lung cancer and melanoma, immunotherapeutics has emerged as a major player in the potential treatment of gliomas, with oncolytic viruses in particular showing significant promise as evidenced by the recent Breakthrough and Fast Tract Designations for PVSRIPO and DNX2401. This review serves as a useful and updated compendium of the completed human clinical investigations for several oncolytic viruses in the treatment of gliomas.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Carpenter AB, Carpenter AM, Aiken R, et al. Oncolytic virus in gliomas: a review of human clinical investigations. Ann Oncol. 2021. PMID: 33771666. doi:10.1016/j.annonc.2021.03.197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。